XNAS
IVF
Market cap491kUSD
Oct 08, Last price
0.74USD
1D
0.35%
1Q
-34.50%
IPO
-99.42%
Name
INVO Bioscience Inc
Chart & performance
P/E
—
P/S
0.07
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.98%
Rev. gr., 5y
45.83%
Revenues
7m
+4.73%
Net income
-23m
L+156.41%
CFO
-7m
L+135.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
INVO Bioscience, Inc. is a globally operating, commercial-phase enterprise focused on fertility, offering advanced solutions in assisted reproductive technology. Their leading product is the INVOcell, an innovative medical device engineered to allow fertilization and the initial development of embryos to naturally occur inside the woman's body. The company, headquartered in Sarasota, Florida, began its operations in 2007.
Key people
Daniel Teper
President, Director · since 2024
Terah Krigsvold
Chief Financial Officer · since 2025
Michael Campbell
Chief Operating Officer, Vice President - Business Development · since 2020
Lyn Falconio
Director · since 2024
Trent Davis
Independent Director · since 2019
Rebecca Messina
Independent Director · since 2021
Barbara Ryan
Independent Director · since 2020
Independent Director · since 2020
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||